{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:14Z","timestamp":1793383154873,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00467-020-04819-6","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T15:02:40Z","timestamp":1604674960000},"page":"711-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults\u2013an update for 2020"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0839-4310","authenticated-orcid":false,"given":"Clifford E.","family":"Kashtan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"4819_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00467-012-2138-4","volume":"28","author":"CE Kashtan","year":"2013","unstructured":"Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013) Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport syndrome research collaborative. Pediatr Nephrol 28:5\u201311","journal-title":"Pediatr Nephrol"},{"key":"4819_CR2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","volume":"81","author":"O Gross","year":"2012","unstructured":"Gross O, Licht C, Anders HJ, Hoppe B, Beck B, T\u00f6nshoff B, Hocker B, Wydoga S, Ehrich JH, Pape L, Konrad M, Rasher W, Dotsch J, Muller-Wierfel DE, Hoyer P, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Muller GA, Weber M, Study Group Members of the Gesellschart fur Padiatrische Nephrologie (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494\u2013501","journal-title":"Kidney Int"},{"key":"4819_CR3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.2349482","volume":"248","author":"DF Barker","year":"1990","unstructured":"Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990) Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248:1224\u20131227","journal-title":"Science"},{"key":"4819_CR4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1086\/302106","volume":"63","author":"E Boye","year":"1998","unstructured":"Boye E, Mollet G, Forestier L, Cohen-Solal L, Heidet L, Cochat P, Grunfeld JP, Palcoux JB, Gubler MC, Antignac C (1998) Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet 63:1329\u20131340","journal-title":"Am J Hum Genet"},{"key":"4819_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1681\/ASN.V12197","volume":"12","author":"L Heidet","year":"2001","unstructured":"Heidet L, Arrondel C, Forestier L, Cohen-Solal L, Mollet G, Gutierrez B, Stavrou C, Gubler MC, Antignac C (2001) Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 12:97\u2013106","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1083\/jcb.135.5.1403","volume":"135","author":"JH Miner","year":"1996","unstructured":"Miner JH, Sanes JR (1996) Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol 135:1403\u20131413","journal-title":"J Cell Biol"},{"key":"4819_CR7","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1101\/gad.10.23.2981","volume":"10","author":"D Cosgrove","year":"1996","unstructured":"Cosgrove D, Meehan DT, Grunkemeyer JA, Kornak JM, Sayers R, Hunter WJ, Samuelson GC (1996) Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev 10:2981\u20132992","journal-title":"Genes Dev"},{"key":"4819_CR8","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/01.ASN.0000130562.90255.8F","volume":"15","author":"MN Rheault","year":"2004","unstructured":"Rheault MN, Kren SM, Thielen BK, Mesa HA, Crosson JT, Thomas W, Sado Y, Kashtan CE, Segal Y (2004) Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 15:1466\u20131474","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","volume":"63","author":"O Gross","year":"2003","unstructured":"Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63:438\u2013446","journal-title":"Kidney Int"},{"key":"4819_CR10","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/gfh219","volume":"19","author":"O Gross","year":"2004","unstructured":"Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M (2004) Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 19:1716\u20131723","journal-title":"Nephrol Dial Transplant"},{"key":"4819_CR11","doi-asserted-by":"crossref","unstructured":"Gross O, Perin L, Deltas C (2014) Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies. Nephrol Dial Transplant 229 Suppl 4:iv124-130","DOI":"10.1093\/ndt\/gfu028"},{"key":"4819_CR12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ki.2011.452","volume":"81","author":"J Temme","year":"2012","unstructured":"Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, Muller GA, Gross O (2012) Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81:779\u2013783","journal-title":"Kidney Int"},{"key":"4819_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","volume":"11","author":"JP Jais","year":"2000","unstructured":"Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 11:649\u2013657","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2009070784","volume":"21","author":"MR Bekheirnia","year":"2010","unstructured":"Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW (2010) Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 21:876\u2013883","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR15","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1681\/ASN.2018030228","volume":"29","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori T, Nakanishi K, Fujimura J, Ashida A, Kitamura M, Kawano M, Shimabukuro W, Kitabayashi C, Imafuku A, Tamagaki K, Kamei K, Okamoto K, Fujinaga S, Oka M, Igarashi T, Miyazono A, Sawanobori E, Fujimaru R, Shima Y, Matsuo M, Ye MJ, Nozu Y, Morisada N, Kaito H, Ijima K (2018) Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 29:2244\u20132254","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR16","doi-asserted-by":"publisher","unstructured":"Yamamura T, Horinouchi T, Nagano C, Omori T, Sakakibara N, Aoto Y, Ishiko S, Nakanishi N, Shima Y, Nagase H, Takeda H, Rossanti R, Ye M, Nozu Y, Ishimori S, Ninchoji T, Kaito H, Morisada N, Iijima K, Nozu K (2020) Genotype-phenotype correlation and the effects of treatment with angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2020.06.038","DOI":"10.1016\/j.kint.2020.06.038"},{"key":"4819_CR17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"O Gross","year":"2020","unstructured":"Gross O, T\u00f6nshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Zappel H, Hoyer P, Staude H, Konig S, John U, Gellermann J, Hoppe B, Gallano M, Hoecker B, Ehren R, Lerch C, Kashtan CE, Harden M, Boeckhaus J, Friede T, German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators (2020) A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. Kidney Int 97:1275\u20131286","journal-title":"Kidney Int"},{"key":"4819_CR18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","volume":"93","author":"CE Kashtan","year":"2018","unstructured":"Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, Nozu K, Renieri A, Rheault M, Wang F, Gross O (2018) Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 93:1045\u20131051","journal-title":"Kidney Int"},{"key":"4819_CR19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ekir.2018.08.002","volume":"3","author":"J Savige","year":"2018","unstructured":"Savige J (2018) Should we diagnose autosomal dominant Alport syndrome when there is a pathogenic heterozygous COL4A3 or COL4A4 variant? Kidney Int Rep 3:1239\u20131241","journal-title":"Kidney Int Rep"},{"key":"4819_CR20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/gfv325","volume":"31","author":"C Gast","year":"2016","unstructured":"Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, Venkat-Raman G, Ennis S (2016) Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 31:961\u2013970","journal-title":"Nephrol Dial Transplant"},{"key":"4819_CR21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","volume":"380","author":"EE Groopman","year":"2019","unstructured":"Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H, Li Y, Zhang J, Nestor J, Krithivasan P, Lam WY, Mitrotti A, Piva S, Kil BH, Chatterjee D, Reingold R, Bradbury D, DiVecchia M, Snyder H, Mu X, Mehl K, Balderes O, Fasel DA, Weng C, Radharishnan J, Canetta P, Appel GB, Bomback AS, Ahn W, Uy NS, Alam S, Cohen DJ, Crew RJ, Dube GK, Rao MK, Kamalakaran S, Copeland B, Ren Z, Bridgers J, Malone CD, Mebane CM, Dagaonkar N, Fellstrom BC, Haefliger C, Mohan S, Sanna-Cherchi S, Kiryluk K, Fleckner J, March R, Platt A, Goldstein DB, Gharavi AG (2019) Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 380:142\u2013151","journal-title":"N Engl J Med"},{"key":"4819_CR22","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"E W\u00fchl","year":"2009","unstructured":"W\u00fchl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F, ESCAPE Trial Group (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639\u20131650","journal-title":"N Engl J Med"},{"key":"4819_CR23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00467-008-1006-8","volume":"24","author":"K Nakanishi","year":"2009","unstructured":"Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, Japanese Pediatric IgA Nephropathy Study Group (2009) Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 24:845\u2013849","journal-title":"Pediatr Nephrol"},{"key":"4819_CR24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","volume":"80","author":"DS Gipson","year":"2011","unstructured":"Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento S, McMahan JL, Siegel N, D'Agati VD, Frideman AL (2011) Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80:868\u2013878","journal-title":"Kidney Int"},{"key":"4819_CR25","doi-asserted-by":"crossref","first-page":"F120","DOI":"10.1152\/ajprenal.00456.2015","volume":"311","author":"G Jarad","year":"2016","unstructured":"Jarad G, Knutsen RH, Mecham RP, Miner JH (2016) Albumin contributes to kidney disease progression in Alport syndrome. Am J Physiol Renal Physiol 311:F120\u2013F130","journal-title":"Am J Physiol Renal Physiol"},{"key":"4819_CR26","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1681\/ASN.2018010036","volume":"29","author":"SM van den Belt","year":"2018","unstructured":"van den Belt SM, HJL H, Gracchi V, de Zeeuw D, W\u00fchl E, Schaefer F, ESCAPE Trial Group (2018) Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol 29:2225\u20132233","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000266478","volume":"32","author":"T Seeman","year":"2009","unstructured":"Seeman T, Pohl M, Misselwitz J, John U (2009) Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with angiotensin-converting enzyme inhibitors. Kidney Blood Press Res 32:440\u2013444","journal-title":"Kidney Blood Press Res"},{"key":"4819_CR28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00467-013-2490-z","volume":"28","author":"M Giani","year":"2013","unstructured":"Giani M, Mastrangelo A, Villa R, Turolo S, Marra G, Tirelli AS, Hopfer H, Edefonti A (2013) Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-\u03b21. Pediatr Nephrol 28:1837\u20131842","journal-title":"Pediatr Nephrol"},{"key":"4819_CR29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00467-006-0270-8","volume":"21","author":"H Kaito","year":"2006","unstructured":"Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanda K, Przybyslaw Kroi R, Yoshikawa N, Matsuo M (2006) The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 21:1824\u20131829","journal-title":"Pediatr Nephrol"},{"key":"4819_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00467-006-0227-y","volume":"22","author":"M Charbit","year":"2007","unstructured":"Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Gr\u00fcnfeld JP, Niaudet P (2007) Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 22:57\u201363","journal-title":"Pediatr Nephrol"},{"key":"4819_CR31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00467-014-2797-4","volume":"29","author":"M Oka","year":"2014","unstructured":"Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, Morisada N, Yan K, Matsuo M, Yoshikawa N, Vorechovsky I, Iijima K (2014) Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol 29:1535\u20131544","journal-title":"Pediatr Nephrol"},{"key":"4819_CR32","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","volume":"14","author":"JP Jais","year":"2003","unstructured":"Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K, Wieslander K, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2003) X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport syndrome concerted action\u201d study. J Am Soc Nephrol 14:2603\u20132610","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2215\/CJN.01000116","volume":"11","author":"N Kamiyoshi","year":"2016","unstructured":"Kamiyoshi N, Nozu K, Fu XJ, Morisada N, Nozu Y, Ye MJ, Imafuku A, Miura K, Yamamura T, Minamikawa S, Shono A, Ninchoji T, Morioka I, Nakanishi K, Yoshikawa N, Kaito H, Iijima K (2016) Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol 11:1441\u20131449","journal-title":"Clin J Am Soc Nephrol"},{"key":"4819_CR34","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ndt\/gfn681","volume":"24","author":"E Marcocci","year":"2009","unstructured":"Marcocci E, Uliana V, Bruttini M, Artuso R, Silengo MC, Zerial M, Bergesio F, Amoroso A, Savoldi S, Pennesi M, Giachino D, Rombola G, Fogazzi GB, Rosatelli C, Martinhago CD, Carmellini M, Mancini R, Di Costanzo G, Longo I, Renieri A, Mari F (2009) Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant 24:1464\u20131471","journal-title":"Nephrol Dial Transplant"},{"key":"4819_CR35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.10581014","volume":"10","author":"J Savige","year":"2015","unstructured":"Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D (2015) Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 10:703\u2013709","journal-title":"Clin J Am Soc Nephrol"},{"key":"4819_CR36","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1681\/ASN.2012100985","volume":"24","author":"H Storey","year":"2013","unstructured":"Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA (2013) COL4A3\/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol 24:1945\u20131954","journal-title":"J Am Soc Nephrol"},{"key":"4819_CR37","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2215\/CJN.02190312","volume":"7","author":"J Temme","year":"2012","unstructured":"Temme J, Kramer A, Jager KJ, Lange K, Peters F, M\u00fcller GA, Kramar R, Heaf JG, Finne P, Palsson R, Reisaeter AV, Hoitsma AJ, Metcalfe W, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O (2012) Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol 7:1969\u20131976","journal-title":"Clin J Am Soc Nephrol"},{"key":"4819_CR38","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","volume":"369","author":"D de Zeeuw","year":"2013","unstructured":"de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM, BEACON Trial Investigators (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369:2492\u20132503","journal-title":"N Engl J Med"},{"key":"4819_CR39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","volume":"125","author":"IG Gomez","year":"2015","unstructured":"Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S, Nakagawa N, Xin C, Newitt R, Pandya S, Xia TH, Liu X, Borza DB, Grafals M, Shankland SJ, Himmelfarb J, Portilla D, Liu S, Chau BN, Duffield JS (2015) Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 125:141\u2013156","journal-title":"J Clin Invest"},{"key":"4819_CR40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/hum.2018.205","volume":"30","author":"J Guo","year":"2019","unstructured":"Guo J, Song W, Boulanger J, Xu EY, Wang F, Zhang Y, He Q, Wang S, Yang L, Pryce C, Phillips L, MacKenna D, Leberer E, Ibraghimov-Beskrovnaya O, Ding J, Liu S (2019) Dysregulated expression of microRNA-21 and disease-related genes in human patients and in a mouse model of Alport syndrome. Hum Gene Ther 30:865\u2013881","journal-title":"Hum Gene Ther"},{"key":"4819_CR41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s004670050451","volume":"12","author":"CE Kashtan","year":"1998","unstructured":"Kashtan CE, Gubler MC, Sisson-Ross S, Mauer M (1998) Chronology of renal scarring in males with Alport syndrome. Pediatr Nephrol 12:269\u2013274","journal-title":"Pediatr Nephrol"},{"key":"4819_CR42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1042\/CS20191276","volume":"134","author":"H Mabillard","year":"2020","unstructured":"Mabillard H, Sayer JA (2020) SGLT2 inhibitors - a potential treatment for Alport syndrome. Clin Sci (Lond) 134:379\u2013388","journal-title":"Clin Sci (Lond)"},{"key":"4819_CR43","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","volume":"11","author":"T Yamamura","year":"2020","unstructured":"Yamamura T, Horinouchi T, Adachi T, Terakawa M, Takaoka Y, Omachi K, Takasato M, Takaishi K, Shoji T, Onishi Y, Kanazawa Y, Koizumi M, Tomono Y, Sugano A, Shono A, Minamikawa S, Nagano C, Sakakibara N, Ishiko S, Aoto Y, Kamura M, Harita Y, Miura K, Kanda S, Morisada N, Rossanti R, Ye MJ, Nozu Y, Matsuo M, Kai H, Iijima K, Nozu K (2020) Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5. Nat Commun 11:2777","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1007\/s00467-020-04892-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000}}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-020-04819-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T23:03:47Z","timestamp":1669503827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-020-04819-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["4819"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04819-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published: https:\/\/doi.org\/10.1007\/s00467-020-04892-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest. Neither the authors nor their immediate family members have any financial relationships or holdings that influenced the writing of this manuscript or that will be affected by the content of the manuscript if published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}